Cargando…
Switching patients with inflammatory arthritis from Etanercept (Enbrel(®)) to the biosimilar drug, SB4 (Benepali(®)): A single-centre retrospective observational study in the UK and a review of the literature
OBJECTIVE/AIM: SB4 (Benepali(®)), the Etanercept biosimilar, is licenced in the UK for the same indications as the reference product, Enbrel(®). In 2016, the Rheumatology Department at Blackpool Teaching Hospitals switched the Etanercept patients, who gave consent, to SB4. A proportion of these pati...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Mediterranean Journal of Rheumatology (MJR)
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280874/ https://www.ncbi.nlm.nih.gov/pubmed/32524081 http://dx.doi.org/10.31138/mjr.30.1.69 |